Elite Pharmaceuticals Inc (ELTP) Financial Statements (2025 and earlier)

Company Profile

Business Address 165 LUDLOW AVENUE
NORTHVALE, NJ 07647
State of Incorp. NJ
Fiscal Year End March 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2024
Q3
9/30/2024
Q2
6/30/2024
Q1
3/31/2024
Q4
12/31/2023
Q3
9/30/2023
Q2
6/30/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9,5558,4077,1065,8168,6549,077
Cash and cash equivalent9,5558,4077,1065,8168,6549,077
Receivables21,44420,48619,45316,01010,4956,201
Inventory, net of allowances, customer advances and progress billings14,16513,83112,93014,32515,22411,168
Inventory14,16513,83112,93014,32515,22411,168
Other undisclosed current assets1304365241,006356998
Total current assets:45,29443,16140,01437,15734,72927,445
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization2,0101,9762,080408  
Operating lease, right-of-use asset2,0892,2222,3552628
Property, plant and equipment10,17710,57110,17510,0959,77010,098
Intangible assets, net (including goodwill)7,2417,2416,3416,3416,3416,341
Intangible assets, net (excluding goodwill)7,2417,2416,3416,3416,3416,341
Restricted cash and investments   433428423415
Deferred income tax assets20,84422,14322,16120,23419,4332,172
Other undisclosed noncurrent assets5435329472121
Total noncurrent assets:42,90444,68543,63937,54035,99019,055
TOTAL ASSETS:88,19887,84683,65474,69670,71946,499
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities7,6878,8358,01614,77514,7677,804
Accounts payable1,9832,6072,7142,8913,6091,875
Accrued liabilities5,7036,2285,30211,88511,1585,929
Deferred revenue121313131313
Debt732749609344295251
Other undisclosed current liabilities4,4224,4174,4114,0264,0024,009
Total current liabilities:12,85414,01513,05019,15919,07812,077
Noncurrent Liabilities
Long-term debt and lease obligation4,5004,6474,7603,5183,3553,578
Long-term debt, excluding current maturities3,0763,2453,2803,3173,3553,578
Finance lease, liability1,4241,4021,480201  
Liabilities, other than long-term debt23,57710,9348,2615,6063,192727
Deferred revenue  2691216
Operating lease, liability1,7411,8511,957   
Derivative instruments and hedges, liabilities21,8369,0816,2985,5973,179711
Total noncurrent liabilities:28,07715,58013,0219,1246,5474,305
Total liabilities:40,93129,59526,07128,28325,62516,382
Equity
Equity, attributable to parent47,26758,25157,58346,41445,09430,117
Common stock1,0681,0681,0681,0181,0141,014
Treasury stock, value(307)(307)(307)(307)(307)(307)
Additional paid in capital173,315173,263173,211165,418164,809164,766
Accumulated deficit(126,810)(115,773)(116,389)(119,715)(120,421)(135,356)
Total equity:47,26758,25157,58346,41445,09430,117
TOTAL LIABILITIES AND EQUITY:88,19887,84683,65474,69670,71946,499

Income Statement (P&L) ($ in thousands)

12/31/2024
Q3
9/30/2024
Q2
6/30/2024
Q1
3/31/2024
Q4
12/31/2023
Q3
9/30/2023
Q2
6/30/2023
Q1
Revenues18,88018,80331,11215,53914,1578,980
Cost of revenue(10,683)(10,328)(17,907)(8,498)(7,710)(4,230)
Gross profit:8,1978,47513,2047,0416,4474,751
Operating expenses(4,712)(4,611)(6,479)(3,508)(4,522)(3,149)
Operating income:3,4853,8646,7263,5331,9261,602
Nonoperating expense(13,004)(3,016)(11,105)(3,627)(4,658)(305)
Interest and debt expense(33)(35)645(122)(130)(119)
Income (loss) from continuing operations before equity method investments, income taxes:(9,552)813(3,734)(216)(2,863)1,177
Other undisclosed income (loss) from continuing operations before income taxes3335(645)122130119
Income (loss) from continuing operations before income taxes:(9,519)848(4,379)(94)(2,733)1,297
Income tax expense (benefit)(1,517)(232)19,69680117,667(155)
Net income (loss) available to common stockholders, basic:(11,036)61615,31870614,9351,142
Dilutive securities, effect on basic earnings per share  7,9777,2219,6805,402658
Other undisclosed net loss available to common stockholders, diluted  (7,977)(7,782)(9,680)(5,402) 
Net income (loss) available to common stockholders, diluted:(11,036)61614,75670614,9351,800

Comprehensive Income ($ in thousands)

12/31/2024
Q3
9/30/2024
Q2
6/30/2024
Q1
3/31/2024
Q4
12/31/2023
Q3
9/30/2023
Q2
6/30/2023
Q1
Net income (loss):(11,036)61615,31870614,9351,142
Comprehensive income (loss), net of tax, attributable to parent:(11,036)61615,31870614,9351,142

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: